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AbstrACt
Introduction Screening for atrial fibrillation (AF) in people 
≥65 years is now recommended by guidelines and expert 
consensus. While AF is often asymptomatic, it is the 
most common heart arrhythmia and is associated with 
increased risk of stroke. Early identification and treatment 
with oral anticoagulants can substantially reduce stroke 
risk. The general practice setting is ideal for opportunistic 
screening and provides a natural pathway for treatment 
for those identified. This study aims to investigate the 
feasibility of implementing screening for AF in rural general 
practice using novel electronic tools. It will assess whether 
screening will fit within an existing workflow to quickly 
and accurately identify AF, and will potentially inform a 
generalisable, scalable approach.
Methods and analysis Screening with a smartphone 
ECG will be conducted by general practitioners and 
practice nurses in rural general practices in New South 
Wales, Australia for 3–4 months during 2018–2019. Up 
to 10 practices will be recruited, and we aim to screen 
2000 patients aged ≥65 years. Practices will be given 
an electronic screening prompt and electronic decision 
support to guide evidence-based treatment for those with 
AF. De-identified data will be collected using a clinical 
audit tool and qualitative interviews will be conducted 
with selected practice staff. A process evaluation and 
cost-effectiveness analysis will also be undertaken. 
Outcomes include implementation success (proportion of 
eligible patients screened, fidelity to protocol), proportion 
of people screened identified with new AF and rates 
of treatment with anticoagulants and antiplatelets at 
baseline and completion. Results will be compared 
against an earlier metropolitan study and a ‘control’ 
dataset of practices.
Ethics and dissemination Ethics approval was received 
from the University of Sydney Human Research Ethics 
Committee on 27 February 2018 (Project no.: 2017/1017). 
Results will be disseminated through various forums, 
including peer-reviewed publication and conference 
presentations.
trial registration number ACTRN12618000004268; Pre-
results.
IntroduCtIon 
Atrial fibrillation (AF) is the most common 
heart arrhythmia, affecting 33.5 million 
people worldwide.1 A person’s likelihood of 
developing AF increases with age, reaching 
37% for those aged ≥55 years.2 Importantly, 
AF is associated with a fivefold increase in risk 
of stroke.3 4 However, 1.4%–1.6% of the popu-
lation aged ≥65 have undiagnosed AF,5 6 which 
is commonly asymptomatic.7 8 Stroke caused 
by AF is largely preventable with appropriate 
oral anticoagulant (OAC) therapy, which 
can reduce AF-related stroke risk by 64%.9 
Although OAC is strongly recommended 
by clinical practice guidelines for those with 
additional stroke risk factors, as set out in the 
CHA₂DS₂-VASc score,10 11 there has histori-
cally been a large gap between evidence and 
practice with only 60% of eligible patients 
prescribed OAC.12 Recently, there are signs 
of improvement, with a recent Public Health 
England report noting 77.9% of eligible 
patients with AF in England were treated with 
OAC.13 Similar increases in OAC prescription, 
strengths and limitations of this study
 ► New technology is used to quickly and efficiently 
identify and treat atrial fibrillation (AF), within an ex-
isting workflow in the general practice setting.
 ► General practices are ideally placed to screen for 
and diagnose AF, as well to provide a pathway to 
care for those identified during screening.
 ► Conducting the study in the rural setting will inform 
future AF screening policies to extend the evidence 
base beyond metropolitan settings.
 ► A potential limitation is the small size and non-ran-
domised design, which would ideally be overcome in 
a future large-scale study.
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largely due to the introduction of novel OACs, have been 
reported in Spain and Denmark.14 15
Screening for AF in people ≥65 years by opportunistic 
pulse palpation or ECG rhythm strip is now recom-
mended by clinical practice guidelines and international 
expert consensus.11 16 17 Many studies have demon-
strated the effectiveness of opportunistic screening for 
AF in general practice. The SAFE study demonstrated 
that opportunistic screening of patients aged ≥65 years 
by general practitioners (GPs), with a flag prompt on 
the patient file, was an effective screening method.5 AF 
screening in general practice was found to be promising 
during influenza vaccination in the Netherlands,18 and 
was successfully performed by practice nurses in the UK.19 
Our previous research showed AF screening by practice 
nurses to be feasible, both opportunistically and during 
the influenza vaccination period.20 21
With 84% of Australian general practices employing 
practice nurses,22 there is scope for AF screening to be 
performed during existing practice nurse health appoint-
ments. Ideally, practice nurses could screen patients for 
AF during the influenza or shingles vaccination and/or 
coordinated chronic care consultations. These appoint-
ments are already funded by the Australian Government: 
the influenza vaccination is recommended annually 
and provided free for patients aged ≥65 years23; shin-
gles vaccines will be provided free for people aged ≥70 
with a 5-year catch-up programme for people aged 
71–7924; annual health assessments are funded for those 
aged ≥7525; and annual coordination consultations are 
funded by Medicare for patients with chronic conditions 
(eg, diabetes, cardiovascular) on a care plan.26 These are 
all occasions when patients in the target age group are 
likely to be available and receptive to AF screening, in an 
appropriate setting.
While numerous studies have been conducted in 
metropolitan areas, there is a paucity of data regarding 
AF screening in rural areas. A recent systematic review of 
AF screening studies conducted in rural settings acknowl-
edged the need for more information on AF burden and 
risk factors specifically in rural areas.27 In the Australian 
context, it is known that people living in rural areas have 
worse cardiovascular outcomes.28 It has been reported 
that there is a lack of evidence about rural cardiovas-
cular disease prevention and ‘characteristics associated 
with quality of care’, which highlights the need for more 
programmes in rural primary care, especially for high-
risk patients.29 This study aims to implement a screening 
programme with a quality improvement (QI) focus, to 
better inform future AF screening policies to extend the 
evidence base beyond metropolitan settings.
MEthods And AnAlysIs
design
This study, Atrial Fibrillation Screen, Management And 
Guideline Recommended Therapy (AF-SMART II), will 
investigate the feasibility of implementation of an AF 
screening and use of an AF electronic decision support 
tool (EDS), in rural general practices. It is a cross-sec-
tional, observational implementation study of AF 
screening using a smartphone ECG conducted by GPs 
and practice nurses in up to 10 rural general practices 
in New South Wales (NSW), Australia. It is very similar 
to the study protocol used in the AF-SMART study which 
was conducted in eight metropolitan general practices in 
Sydney, Australia from 2016 to 2018. AF-SMART II is a 
rural extension of AF-SMART with some important modi-
fications based on feedback obtained in the metropol-
itan study. These modifications include: (1) an improved 
electronic screening prompt to improve the proportion 
of eligible patients screened; (2) the introduction of GP 
continuing professional development (CPD)/QI points 
to provide additional incentives for GPs; (3) a more struc-
tured approach to nurse screening and (4) a shorter 
screening period.
Practice recruitment
A convenience sample of up to 10 rural general practices, 
recruited through several NSW Primary Health Networks, 
will be invited to participate in the study. Practices will be 
required to:
 ► Have at least one practice nurse.
 ► Use either ‘Best Practice’ or ‘Medical Director’ as 
the practice electronic patient record management 
system.
 ► Be willing to have ‘TopBar’ (PenCS third party soft-
ware) and the clinical audit tool ‘PenCAT’ for data 
collection installed (licences are provided by the 
Primary Health Networks, NSW).
 ► Have WiFi.
Preintervention: training and set up electronic study tools
Once a practice has been recruited, the preintervention 
phase will involve setting up the electronic study tools 
and relevant training. Each practice will be provided 
with several Kardia smartphone ECG (iECG) devices to 
screen for AF (figure 1). This device has approval from 
the Australian Therapeutic Goods Administration as a 
Medical Device, Class IIa and has a validated, automated 
algorithm for detecting AF with 95% sensitivity and 99% 
specificity.21
In addition, practices will be provided with two 
custom-designed apps that were developed and tested in 
the AF-SMART study (figures 2 and 3). These apps are 
the:
1. AF app with screening prompt, which extracts data 
from the electronic patient record and provides a 
prompt for AF screening when an eligible patient’s file 
is opened, and allows clinical staff to record the provi-
sional screening results (figures 2 and 3).
2. EDS system, which guides evidence-based treatment 
of those diagnosed with AF. The EDS is a clinically 
validated QI tool, designed to bridge gaps between 
evidence and practice in AF risk management.30 The 
EDS extracts data from electronic patient records 
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regarding current OAC and antiplatelet prescriptions 
and calculates individual stroke risk scores (CHA2DS2-
VASc) (figure 4). It then provides clinical staff with 
evidence-based medication guidelines to support deci-
sions on OAC prescription.
The apps are located in the TopBar hosting platform 
that integrates with the general practice electronic patient 
record management systems.
Once the technology set-up is complete, practice 
nurses and GPs will receive training on the use of the 
electronic tools and iECG as well as recent develop-
ments in evidence-based management of AF for stroke 
prevention, highlighting guideline recommendations 
for OAC, and recommendations against using aspirin 
to treat AF.11 Practices will be provided with posters for 
the reception area advertising the study and a laminated 
participant information statement will be available at 
reception.
Patient eligibility
All patients aged ≥65 years presenting to the general 
practice for annual influenza vaccination, shingles vacci-
nation, chronic care assessment or seeing their GP, will 
be eligible for AF screening if they meet the following 
criteria:
 ► Age ≥65 years.
 ► No current recorded diagnosis of AF.
 ► Have not already been screened with the iECG in the 
past 12 months.
Patients with terminal illness and patients unable to 
provide informed consent will be excluded.
screening protocol
The screening intervention will be conducted for a period 
of 3–4 months in each practice. The process is shown in 
figure 5, and summarised below:
 ► The AF screening prompt will notify clinical staff a 
patient is eligible for iECG screening.
 ► The GP/nurse will explain the screening process 
and purpose, and obtain informed oral consent from 
patients.
 ► The GP/nurse will record a 30 s iECG. The iECG trace 
will be visible in real time on the phone, and a pdf will 
also be available to download from the secure Kardia 
website. An automated interpretation (‘Possible AF’, 
‘Normal’ or ‘Unclassified’) is provided immediately 
after successful recording.
 ► The GP/nurse will enter the iECG screening result 
into the AF app in TopBar.
 ► Depending on the iECG result, follow the appropriate 
protocol.
Figure 1 Kardia device and iECG reading.
Figure 2 Screenshot showing test patient file and TopBar apps. AF, atrial fibrillation.
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Protocol if a patient receives ‘possible AF’ diagnosis
The GP/nurse will inform the patient of the diagnosis 
and give a brief explanation. If the nurse performed the 
screening, the patient will be referred to their GP. Further 
investigation and management is at the GP’s discretion, 
which could include referral to a specialist. A 12-lead ECG 
is recommended to provide additional confirmation for all 
new AF diagnoses, and to add extra leads for AF diagnostic 
workup. In some cases of paroxysmal AF, the 12-lead ECG 
may show sinus rhythm while the iECG showed AF. This will 
be obvious from a comparison of the p-waves on the lead I 
iECG and lead I of the 12-lead ECG, as well as the regularity 
of the rhythm. Following a 12-lead ECG, for patients with 
confirmed AF, GPs will be encouraged to use the EDS to 
Figure 3 entering an iECG result in TopBar AF app (test patient shown). AF, atrial fibrillation; GP, general practitioner. 
Figure 4 Screenshot showing EDS recommendation for test patient. AF, atrial fibrillation; NOAC, novel oral anticoagulant.
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review each patient’s CHA₂DS₂-VASc score and commence 
guideline-recommended treatment to reduce stroke risk.
Protocol if a patient receives ‘normal’ diagnosis
The GP/nurse will inform the patient of the diagnosis. 
No further action is required.
Protocol if a patient receives ‘unclassified’ diagnosis
The GP/nurse will inform the patient of the diagnosis and 
give a brief explanation based on information provided 
by researchers. Depending on individual patient’s history 
and iECG, a 12-lead ECG may be recommended by the 
GP but follow-up is at the GP’s discretion. There are a 
Figure 5 Process flow of AF screening. AF, atrial fibrillation; GP, general practitioner; OAC, oral anticoagulant.
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number of conditions that can lead to this particular 
diagnosis (eg, sinus tachycardia/bradycardia, left bundle 
branch block, right bundle branch block or multiple 
ectopic beats) which may or may not be clinically signifi-
cant, or previously known.
CPd and QI points
In order to assist in practice recruitment, education and 
training will be structured to be eligible for CPD points 
for nurses and GPs. In addition, all practices will be 
encouraged to use the research project to conduct an AF 
QI  programme that will attract specific QI professional 
development points.
study outcomes
 ► Implementation success through process measures 
including proportion of eligible patients seen in the 
practice during the period who are screened (calcu-
lated from information available in the de-identified 
data extracts), fidelity to the protocol and time taken 
to complete the intervention.
 ► Proportion of people screened identified with new AF.
 ► Proportion of patients where EDS page accessed.
 ► Proportion of eligible patients prescribed OAC as a 
result of the intervention.
 ► Proportion of patients with diagnosed AF prescribed 
antiplatelet therapy during the study period.
 ► Prevalence of AF at baseline (compared with metro-
politan and control group, as defined below).
 ► Incidence of new AF at completion of the intervention 
(compared with metropolitan and control group).
 ► Rates of treatment with anticoagulants and antiplate-
lets at baseline and at completion of the intervention 
(compared with metropolitan and control group).
 ► Acceptability, competing demands, barriers and 
enablers according to staff involved in the intervention.
 ► Cost-effectiveness analysis (ie, incremental cost-effec-
tiveness ratio (ICER) of screening per quality-adjusted 
life year (QALY) gained and per stroke avoided), using 
data from Cadilhac et al31 to estimate the present value 
of QALYs gained for each ischaemic stroke prevented.
data collection and sample size
The study aims to screen approximately 2000 patients in 
total from up to 10 general practices. Assuming an inci-
dence of 1.4% of people aged ≥65 with unknown AF,32 we 
estimate 28 new cases of AF would be identified. A sample 
size of 2000, assuming 1.4% incidence, would provide a 
95% CI of 0.93% to 2.02% (18–40 cases).
PenCAT will be configured to collect de-identified 
data from electronic patient records. These data include 
demographic, medication and diagnostic information. 
Data extracts will be taken at baseline, end of month 
1, end of month 2 and end of month 3. The screening 
period will be extended if required so that practices get 
all four data extracts. Following each data extract, feed-
back will be provided to practices including a summary of 
results (number screened by each staff member in total 
and for that month).
Following completion of the iECG screening period, 
selected staff from each practice will be interviewed to 
gather their feedback as part of a comprehensive process 
evaluation. Semistructured interviews with selected GPs, 
practice nurses and practice managers will be carried out 
by researchers at the end of the screening intervention. 
The interviews will be audio recorded and transcribed.
statistical analysis
Quantitative analysis
Descriptive analyses will be carried out both at the indi-
vidual practice level and all practices pooled together. 
Data collected in this study will be compared with data 
collected from the earlier study in metropolitan Sydney, 
and a database of ‘control’ practices with the same 
data-parameters collected through concurrent studies 
run by The George Institute. Analyses of these data will 
be conducted using SAS v 9.4, with χ2 tests used to test 
associations between AF incidence and method of detec-
tion (screen detected or clinically detected), and two-tail 
p values<0.05 will be considered significant.
Cost-effectiveness analysis
A basic economic model for AF screening has previously 
been developed and used in the SEARCH-AF33 study. This 
model will be adapted and extended to evaluate screening 
for AF by the practice nurse in the general practice. A 
modelled cost-effectiveness analysis from an Australian 
health funder perspective will be performed comparing 
the cost of iECG population-based screening for AF, to 
diagnosed AF in an unscreened population of Australian 
men and women aged 65–84 years. Future costs will be 
discounted at a rate of 5%. The results will be expressed 
as an ICER per stroke avoided and per QALY gained.
Sensitivity analyses will be performed, including varying 
the base assumptions of a guideline-adherence rate for 
OAC prescription from 40% to 90% and increasing the 
cost of treatment. We will obtain 95% CIs for all ICERs 
using a multifactorial Monte Carlo simulation34 as 
described in SEARCH-AF.33
Qualitative analysis
A detailed process evaluation using mixed methods will 
be undertaken to evaluate the iECG screening process. 
Realist evaluation35 will be used to analyse the interaction 
of context, mechanisms for change and the outcomes 
that are produced in both this study and the metropolitan 
component. In this way, we will piece together a detailed 
understanding of how the intervention influenced the 
capacity, opportunity and motivation of providers to 
improve detection and evidence-based treatment of AF.
Patient involvement
Development and refinement of the protocol was an 
iterative process. Feedback obtained through inter-
views patients, nurses, GPs and practice managers about 
their experience and preferences during previous AF 
screening studies,20 21 contributed to the development of 
the protocol. Following the study, participating practices 
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will be provided with a summary of the findings of the 
study, together with a full copy of any publications, which 
will be made available to patients in the practice recep-
tion area.
EthICs And dIssEMInAtIon
The study will comply with the National Health and 
Medical Research Council ethical guidelines. Partici-
pating practices will provide written, informed consent 
and patients being screened will provide oral consent. We 
used the Standard Protocol Items: Recommendations for 
Interventional Trials checklist when writing our protocol 
report.36 The study will be administered by the Charles 
Perkins Centre, University of Sydney. Results of the study 
will be disseminated through various forums, including 
peer-reviewed publications and presentation at national 
and international conferences.
ConClusIons
Screening for AF in people ≥65 years is now recom-
mended by guidelines and international expert 
consensus.11 16 Importantly, a comprehensive screening 
programme should include a system to support evidence-
based treatment for patients ultimately diagnosed with 
the condition.16 General practices are well placed to 
opportunistically screen older patients, and are ideal in 
terms of the pathway for treatment for those identified. 
This study will provide electronic prompts for screening 
and test a patient-level EDS integrated with the practice’s 
clinical software, to support evidence-based treatment.
In previous studies, a range of evidence-based interven-
tions has been developed to increase effective prescribing 
of guideline-recommended OAC in primary care settings. 
These include use of EDS tools,37 targeted GP-education 
programmes,38 consultant-led primary care anticoagula-
tion assessment clinics39 and patient-focused education 
interventions.40 Overall, these interventions increase 
quality prescribing, but the results are varied in terms of 
effect size and duration. One study with a large effect size 
used a consultant-led anticoagulation assessment within 
the general practice to identify and review patients with 
AF with a CHA₂DS₂-VASc score ≥1 who were ‘suboptimally 
anticoagulated’.39 This study reported a substantial and 
significant increase in appropriate OAC treatment from 
77% to 95% (p<0.0001), suggesting that an intensive, 
systematic approach, together with numerous reminders 
to improve patient attendance at in-person reviews, can be 
very successful in increasing OAC uptake.39 In contrast, a 
cluster-randomised study providing doctors with patient-
level recommendations via an EDS did not show signifi-
cant improvements in evidence-based OAC treatment.37
This study aims to investigate the feasibility of imple-
menting screening for AF in rural general practice. It 
follows on from the first phase of the study conducted 
in metropolitan general practice, allowing comparison 
against a metropolitan setting and a control group of 
standard practices. The project will assess if screening 
will efficiently fit within an existing workflow to quickly 
and accurately identify AF. The study will also explore 
the effect of GP and practice nurse education, electronic 
screening prompts and EDS to facilitate evidence-based 
treatment.
In Australia, the Heart Foundation’s Guideline for the 
Diagnosis and Management of Atrial Fibrillation will be 
released in August 2018, the draft guideline recommends 
opportunistic screening for AF in general practice for 
people aged ≥65 years. This study will potentially have 
important implications for the implementation of a large 
scale opportunistic AF screening programme for those 
aged ≥65 years. It could also inform the design of a future 
randomised trial of AF screening. It is anticipated that the 
study will demonstrate that the general practice setting, 
provided with additional electronic tools, can meet the 
challenges of large-scale opportunistic screening with a 
cheap, convenient, scalable solution.
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